Fampridine Newbury approved by the Swedish Health Authorities
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Newbury Pharmaceuticals via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2022-12-27 10:00:00
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Fampridine Newbury 10 mg prolonged-release tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals in Norway and Denmark are expected to follow upon finalized national reviews.
“The approval of Fampridine Newbury is the 2nd product approved for the treatment of multiple sclerosis following the approval of Teriflunomide Newbury in October this year and it further shows our commitment within the field of Neurology. Multiple sclerosis is a serious life changing disease where the company aims to provide cost efficient alternatives to current treatments. Based on this positive progress, we will proceed to launch this product, within respective markets, as soon as regulatory exclusivities and patents allow us.” Says Mr. Lars Minor, CEO of Newbury.
Fampridine Newbury is a medicine used to improve walking ability in adults with multiple sclerosis (MS) who have a walking disability. It contains the active substance fampridine.
MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves. Multiple sclerosis is characterized by immune-mediated inflammation and neurodegeneration. It is a disease of unknown aetiology.